Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colonic Neoplasms 2Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Sorafenib 20lenvatinib 18Hepatectomy 17Blood Specimen Collection 12Immune Checkpoint Inhibitors 11atezolizumab 9Liver Transplantation 9Surgical Procedures, Operative 7Radiofrequency Ablation 7Observation 7Bevacizumab 7regorafenib 5gadolinium ethoxybenzyl DTPA 5sintilimab 4donafenib 4camrelizumab 4Radiotherapy 4Magnetic Resonance Spectroscopy 4tislelizumab 3spartalizumab 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Mass Spectrometry 3Immunohistochemistry 3Doxorubicin 3Angiogenesis Inhibitors 3toripalimab 2pembrolizumab 2entecavir 2apatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma, Hepatocellular × Cytidine Triphosphate × Clear all
NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡